← Back to Volume 10, Issue 1

Physiological Mechanisms and Intervention Strategies for the Increased Cardiovascular Risk in Perimenopausal Women

Jiayi Chen
Vol.10, No.1, pp.69-76, 2026 DOI: 10.62051/ijsspa.v10n1.09 January 29, 2026
Download PDF
Abstract: Cardiovascular disease (CVD) is the leading cause of female mortality worldwide, and risk rises sharply during the perimenopausal transition as circulating estrogen declines. This review synthesizes macro-to-micro physiological mechanisms linking estrogen loss to vascular and cardiac dysfunction, including adverse shifts in blood pressure and lipid profiles, increased arterial stiffness, endothelial nitric oxide (NO) impairment, heightened oxidative stress with mitochondrial dysfunction, pro-fibrotic remodeling, and reduced angiogenic repair capacity. We further discuss how differential signaling through ERα, ERβ, and G protein–coupled estrogen receptor (GPER) contributes to heterogeneous cardioprotective effects across individuals and clinical phenotypes. Current intervention strategies are evaluated, emphasizing additive benefits of lifestyle modification and guideline-directed pharmacotherapies (e.g., statins and antihypertensives) for risk reduction. Hormone replacement therapy (HRT) remains controversial; evidence supports a timing-dependent “critical window” in which early initiation near menopause may confer vascular benefit, whereas late initiation offers limited protection and may increase thrombotic or cerebrovascular risk depending on formulation and route. Finally, we highlight emerging biomedical engineering approaches-particularly AI-enabled risk stratification using electronic health records, wearable data, and imaging biomarkers-as promising tools to enable earlier detection and personalized prevention for perimenopausal women.
Keywords: Perimenopause, Estrogen, Cardiovascular Disease, Endothelial Dysfunction, Arterial Stiffness, Hormone Replacement Therapy, Timing Hypothesis
APA Citation: Jiayi Chen (2026). Physiological Mechanisms and Intervention Strategies for the Increased Cardiovascular Risk in Perimenopausal Women. International Journal of Social Sciences and Public Administration, 10(1), 69-76. https://doi.org/10.62051/ijsspa.v10n1.09

References

  1. Garcia, M., Mulvagh, S. L., Merz, C. N., Buring, J. E., & Manson, J. E. (2016). Cardiovascular disease in women: Clinical perspectives. Circulation Research, 118(8), 1273–1293. https://doi.org/10.1161/CIRCRESAHA.116.307547
  2. Ryczkowska, K., Adach, W., Janikowski, K., Banach, M., & Bielecka-Dabrowa, A. (2022). Menopause and women's cardiovascular health: Is it really an obvious relationship? Archives of Medical Science, 19(2), 458–466. https://doi.org/10.5114/aoms/157308
  3. Raj, A., Chakole, S., Agrawal, S., et al. (2023). The impact of menopause on cardiovascular aging: A comprehensive review of androgen influences. Cureus, 15(8), e43569. https://doi.org/10.7759/cureus.43569
  4. Witting, C., Devareddy, A., & Rodriguez, F. (2022). Review of lipid-lowering therapy in women from reproductive to postmenopausal years. Reviews in Cardiovascular Medicine, 23(5), 183. https://doi.org/10.31083/j.rcm2305183
  5. Wassertheil-Smoller, S., Psaty, B., Greenland, P., et al. (2004). Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA, 292(23), 2849–2859. https://doi.org/10.1001/jama.292.23.2849
  6. Gabriel, S. R., Carmona, L., Roque, M., Sánchez, G. L., & Bonfill, X. (2005). Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews, 2005(2), CD002229. https://doi.org/10.1002/14651858.CD002229.pub2
  7. Flores, V. A., Pal, L., & Manson, J. E. (2021). Hormone therapy in menopause: Concepts, controversies, and approach to treatment. Endocrine Reviews, 42(6), 720–752. https://doi.org/10.1210/endrev/bnab011
  8. Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., & Eghbali, M. (2017). The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biology of Sex Differences, 8(1), 33. https://doi.org/10.1186/s13293-017-0152-8
  9. What is biomedical engineering? https://drexel.edu/biomed/resources/what-is-biomedical-engineering/
  10. Mendelsohn, M. E., & Karas, R. H. (1999). The protective effects of estrogen on the cardiovascular system. The New England Journal of Medicine, 340(23), 1801–1811. https://doi.org/10.1056/NEJM199906103402306
  11. Tran, T. T. T., Phung, T. M., Do, A. T. M., Ly, Q. T. M., & Nguyen, T. H. (2025). Menopausal hormone therapy: Its role in the prevention of cardiovascular diseases and the risk of breast cancer in women. Clinical and Experimental Obstetrics & Gynecology, 52(1), 26813. https://doi.org/10.31083/CEOG26813
  12. Karim, R., Xu, W., Kono, N., et al. (2022). Effect of menopausal hormone therapy on arterial wall echomorphology: Results from the Early versus Late Intervention Trial with Estradiol (ELITE). Maturitas, 162, 15–22. https://doi.org/10.1016/j.maturitas.2022.02.007
  13. Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. The New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
  14. Boardman, H. M., Hartley, L., Eisinga, A., et al. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews, 2015(3), CD002229. https://doi.org/10.1002/14651858.CD002229.pub4
  15. Giri, R., & Vincent, A. J. (2020). Prevalence and risk factors of premature ovarian insufficiency/early menopause. Seminars in Reproductive Medicine, 38(4–5), 237–246. https://doi.org/10.1055/s-0040-1722317
  16. Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040
  17. Wassertheil-Smoller, S., Hendrix, S., Limacher, M., et al. (2003). Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative randomized trial. JAMA, 289(20), 2673–2684. https://doi.org/10.1001/jama.289.20.2673
  18. Study NCT06802484. https://ichgcp.net/clinical-trials-registry/NCT06802484
  19. Valenti, V. E., Candeloro, B. M., Raimundo, R. D., et al. (2025). The impact of exercise on cardiovascular parameters in postmenopausal women: A narrative review. Maturitas, 201, 108688. https://doi.org/10.1016/j.maturitas.2025.108688
  20. U.S. Preventive Services Task Force. (2022). Statin use for the primary prevention of cardiovascular disease in adults: U.S. Preventive Services Task Force recommendation statement. JAMA, 328(8), 746–753. https://doi.org/10.1001/jama.2022.13044
  21. Herrington, D. M., Vittinghoff, E., Lin, F., et al. (2002). Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation, 105(25), 2962–2967. https://doi.org/10.1161/01.cir.0000019585.84624.2d
  22. Moon, J., Yoo, S., Koh, G., Min, K. W., & Shin, H. H. (2020). Efficacy and safety of high-dose atorvastatin in moderate-to-high cardiovascular risk postmenopausal Korean women with dyslipidemia. Journal of Lipid and Atherosclerosis, 9(1), 162–171. https://doi.org/10.12997/jla.2020.9.1.162
  23. Ettehad, D., Emdin, C. A., Kiran, A., et al. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. The Lancet, 387(10022), 957–967. https://doi.org/10.1016/S0140-6736(15)01225-8
  24. Hsu, C. Y., Saver, J. L., Ovbiagele, B., Wu, Y. L., Cheng, C. Y., & Lee, M. (2023). Association between magnitude of differential blood pressure reduction and secondary stroke prevention: A meta-analysis and meta-regression. JAMA Neurology, 80(5), 506–515. https://doi.org/10.1001/jamaneurol.2023.0218
  25. Davis, J. W., Weller, S. C., Porterfield, L., Chen, L., & Wilkinson, G. S. (2023). Statin use and the risk of venous thromboembolism in women taking hormone therapy. JAMA Network Open, 6(12), e2348213. https://doi.org/10.1001/jamanetworkopen.2023.48213
  26. Manson, J. E., Ames, J. M., Shapiro, M., et al. (2015). Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: A clinical decision-support tool from The North American Menopause Society. Menopause, 22(3), 247–253. https://doi.org/10.1097/GME.0000000000000373
  27. My Life Check | Life’s Simple 7. (2021). American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/my-life-check--lifes-simple-7
  28. Guo, Y., Lane, D. A., Wang, L., et al. (2020). Mobile health technology to improve care for patients with atrial fibrillation. Journal of the American College of Cardiology, 75(13), 1523–1534. https://doi.org/10.1016/j.jacc.2020.01.052
  29. Wang, J., Ding, H., Bidgoli, F. A., Zhou, B., Iribarren, C., Molloi, S., & Baldi, P. (2017). Detecting cardiovascular disease from mammograms with deep learning. IEEE Transactions on Medical Imaging, 36(5), 1172–1181. https://doi.org/10.1109/TMI.2017.2655486